42 unknown, 16 recruiting, 15 not yet recruiting, 7 completed. 45 Phase 2, 37 Phase 1, 24 Phase 3, 2 Not applicable, 2 Phase 4.
Follow Sinocelltech Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, PK/PD Characteristics, and Efficacy of SCTB10 SCTB10, Placebo - Healthy Participants | Phase 1 | Not yet recruiting | Sinocelltech Ltd. | 12 | 2026-09-30 | 2026-09-29 |
| SCTB35 and SCTB41 With or Without Chemotherapy in Non-Hodgkin Lymphoma SCTB35 injection, SCTB41 - NHL - Non-Hodgkin's Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Sinocelltech Ltd. | 90 | 2026-09-30 | 2026-09-14 |
| SCTB41 Plus SCTB39G With or Without Standard Therapy in Advanced Solid Tumors SCTB41+SCTB39G - Advanced Malignant Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Sinocelltech Ltd. | 112 | 2026-06-30 | 2026-06-26 |
| A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma SCTB35 injection, Rituximab, Lenalidomide - Follicular Lymphoma (FL) | Phase 3 | Recruiting | Sinocelltech Ltd. | 93 | 2026-06-09 | 2026-08-13 |
| A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma SCTB35 injection, Rituxumab, Gemcitabine - DLBCL - Diffuse Large B Cell Lymphoma | Phase 3 | Recruiting | Sinocelltech Ltd. | 101 | 2026-06-04 | 2026-08-13 |
| Phase I/II Study of SCTB41 Plus SCTB39-1with or Without Standard Therapy in Advanced Solid Tumours SCTB41+SCTB39-1 - Advanced Malignant Solid Tumor | Phase 1 / Phase 2 | Not yet recruiting | Sinocelltech Ltd. | 126 | 2026-05-30 | 2026-05-18 |
| SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer SCTB41, Tislelizumab, Paclitaxel - Double Blind | Phase 2 / Phase 3 | Recruiting | Sinocelltech Ltd. | 410 | 2026-05-09 | 2026-06-23 |
| A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing） SCTB41, docetaxel - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 | Not yet recruiting | Sinocelltech Ltd. | 90 | 2026-05-01 | 2026-05-27 |
| A Clinica Study of SCTC21C in Participants With Systemic Lupus Erythematosus SCTC21C - Systemic Lupus Erythematosus (SLE) | Phase 1 / Phase 2 | Not yet recruiting | Sinocelltech Ltd. | 159 | 2026-04-01 | 2026-04-20 |
| Study of Ripertamab in Children With Frequent Relapses or Steroid-Dependent Nephrotic Syndrome ripertamab - FRNS/SDNS, Ripertamab | Not applicable | Not yet recruiting | Mao Jianhua | 312 | 2026-02-01 | 2026-02-05 |
| A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA) SCTC21C, Bortezomib, Dexamethasone - Amyloidosis | Phase 3 | Recruiting | Sinocelltech Ltd. | 90 | 2026-01-08 | 2026-02-05 |
| A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer. SCTB14, Pembrolizumab - Non-Small Cell Lung Carcinoma (NSCLC) | Phase 3 | Recruiting | Sinocelltech Ltd. | 246 | 2025-12-30 | 2026-01-23 |
| A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant SCTC21C, Bortezomib, Lenalidomide - Multiple Myeloma (MM) | Phase 3 | Recruiting | Sinocelltech Ltd. | 292 | 2025-12-29 | 2026-01-29 |
| Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa SCT650C - Hidradenitis Suppurativa (HS) | Phase 2 | Recruiting | Sinocelltech Ltd. | 60 | 2025-12-16 | 2026-04-28 |
| Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC Stapokibart and Finotonlimab - HNSCC | Phase 1 | Recruiting | Beijing Tongren Hospital | 10 | 2025-10-09 | 2026-05-04 |
| Phase I/II Study of SCTB39G in Advanced Solid Tumours SCTB39G - Advanced Malignant Solid Tumor | Phase 1 / Phase 2 | Not yet recruiting | Sinocelltech Ltd. | 30 | 2025-07-28 | 2025-07-22 |
| Phase I/II Study of SCTB39-1 in Advanced Solid Tumours SCTB39-1 - Advanced Malignant Solid Tumor | Phase 1 / Phase 2 | Recruiting | Sinocelltech Ltd. | 110 | 2025-06-23 | 2025-07-04 |
| A Study of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease. SCTT11, Placebo - TED | Phase 1 / Phase 2 | Not yet recruiting | Sinocelltech Ltd. | 100 | 2025-02-19 | 2025-01-10 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine Recombinant Herpes Zoster Vaccine (SCTV04C) Low-Dose, Recombinant Herpes Zoster Vaccine (SCTV04C) High-Dose, Placebo control: Saline - Herpes Zoster | Phase 1 / Phase 2 | Not yet recruiting | Sinocelltech Ltd. | 540 | 2025-02-15 | 2025-01-30 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine SCTV02, Placebo - Respiratory Syncytial Virus | Phase 1 / Phase 2 | Recruiting | Sinocelltech Ltd. | 480 | 2025-02-06 | 2025-02-13 |
Showing 20 of 86. Sign in to see all of them.
COVID-19 (21) · Hemophilia A (6) · Carcinoma, Non-Small-Cell Lung (4) · Squamous Cell Carcinoma of Head and Neck (4) · Carcinoma, Squamous Cell (3) · Colorectal Neoplasms (3) · Neoplasms (3) · Esophageal Squamous Cell Carcinoma (2) · Head and Neck Neoplasms (2) · Lupus Erythematosus, Systemic (2) · Lymphoma, B-Cell (2) · Lymphoma, Non-Hodgkin (2) · Amyloidosis (1) · Autoimmune Diseases (1) · Axial Spondyloarthritis (1)
SCTV01C vaccine (15) · BNT162 Vaccine (6) · upanovimab (5) · Docetaxel (3) · Paclitaxel (3) · Rituximab (3) · Bevacizumab (2) · Bortezomib (2) · Carboplatin (2) · Dexamethasone (2) · Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (2) · Lenalidomide (2) · 130-nm albumin-bound paclitaxel (1) · 2019-nCoV Vaccine mRNA-1273 (1) · Adalimumab (1)
China (53) · United Arab Emirates (3) · Turkey (Türkiye) (2) · Argentina (1) · Australia (1) · Brazil (1) · Chile (1) · Colombia (1) · Mexico (1) · Peru (1) · United States (1)
Renchi Yang (3) · Yuankai Shi, MD (3) · Yang Wang, Ph.D. (2) · Zhanghua Lan, PhD (2) · Bo Zhou, M.D. (1) · Fengcai Zhu (1) · Guohua Li (1) · Han Baohui, M.D. (1) · Hong Zhang (1) · Lei Zhang (1) · Luo Zhang (1)
PMID 34473343, PMID 16753240, PMID 21142263, PMID 41495391, PMID 27503625, PMID 34491805, PMID 36307775, PMID 36403700, PMID 36470077, PMID 36598621, PMID 37247166, PMID 37731938, PMID 38148327, PMID 38942993, PMID 39230871, PMID 39834144, PMID 39892704, PMID 40386729, PMID 40520909, PMID 40769977, PMID 40819238, PMID 41012186, PMID 42668534, PMID 42706605